Sinopharm Tech Holdings (HKSE:08156) 3-Year EBITDA Growth Rate : 81.90% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Sinopharm Tech Holdings 3-Year EBITDA Growth Rate?

Sinopharm Tech Holdings's EBITDA per Share for the three months ended in Dec. 2023 was HK$0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 81.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 42.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sinopharm Tech Holdings was 81.90% per year. The lowest was -81.40% per year. And the median was -10.30% per year.

Competitive Comparison of Sinopharm Tech Holdings's 3-Year EBITDA Growth Rate

For the Software - Application subindustry, Sinopharm Tech Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinopharm Tech Holdings's 3-Year EBITDA Growth Rate Distribution in the Software Industry

For the Software industry and Technology sector, Sinopharm Tech Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sinopharm Tech Holdings's 3-Year EBITDA Growth Rate falls into.

Sinopharm Tech Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sinopharm Tech Holdings (HKSE:08156) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sinopharm Tech Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sinopharm Tech Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinopharm Tech Holdings (HKSE:08156) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Sinopharm Tech Holdings Ltd (HKSE:08156) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ruttonjee Centre, 11 Duddell Street, Unit 1802, 18/F, Ruttonjee House, Hong Kong Central, Hong Kong, HKG

Website

https://www.sinopharmtech.com.hk

Sinopharm Tech Holdings Ltd is an investment holding company. The company's operating segment includes Lottery-related services; Provision of Internet Plus services (solution and supply chain), Manufacturing and distribution of personal protective equipment, and Others services. It generates maximum revenue from the internet plus services (solution and supply chain) segment. The Internet plus Supply chain services segment includes the provision of supply chain management, data analysis and related services, and trading of goods through the internet platform. Geographically, it derives a majority of revenue from Hong Kong.

Executives

Best Frontier Investments Limited
Chan Kin Ho Philip	2201 Interest of corporation controlled by you
Lam Yui Keung	2201 Interest of corporation controlled by you
Sinopharm Traditional Chinese Medicine Overseas Holdings Limited	2101 Beneficial owner
Main Key Investments Limited	2201 Interest of corporation controlled by you
Guo Lei	2201 Interest of corporation controlled by you
Integrated Asset Management (asia) Limited	2101 Beneficial owner
Yam Tak Cheung	2201 Interest of corporation controlled by you
Chan Tung Mei	2202 Interest of your spouse
Cheung Kwai Lan	2201 Interest of corporation controlled by you
Tse Siu Hoi	2101 Beneficial owner
Gam Star China Equity (a Sub-fund Of Gam Star Fund P.l.c.)	2102 Investment manager

Sinopharm Tech Holdings (HKSE:08156) Headlines

No Headlines